News Image

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

Provided By GlobeNewswire

Last update: Apr 22, 2025

WASHINGTON, April 22, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced findings that the actual burden of babesiosis in the United States (U.S.) may be significantly higher than Centers for Disease Control and Prevention (CDC) statistics suggest. Preliminary results of an online survey conducted by the Company showed that nearly 3 million Americans (1.26 percent of the adult population in 2020) may have received a babesiosis diagnosis from a medical practitioner in their lifetime.

Read more at globenewswire.com

60 DEGREES PHARMA INC-28

NASDAQ:SXTPW (7/25/2025, 2:48:38 PM)

0.0445

-0.03 (-36.25%)


60 DEGREES PHARMA INC

NASDAQ:SXTP (7/25/2025, 3:21:49 PM)

1.325

-0.02 (-1.12%)



Find more stocks in the Stock Screener

Follow ChartMill for more